This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012; 82: e17-24. doi: 10.1016/j.ijrobp.2010.10.075MiralbellRRobertsSAZubizarretaEHendryJHDose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy201215e172410.1016/j.ijrobp.2010.10.07521324610Open DOISearch in Google Scholar
Daşu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol 2007; 19: 289-301. doi: 10.1016/j. clon.2007.02.007DaşuA.Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?20071928930110.1016/j.clon.2007.02.00717517328Open DOISearch in Google Scholar
Datta NR, Stutz E, Rogers S, Bodis S. Clinical estimation of α/β values for prostate cancer from isoeffective phase III randomized trials with moderately hypofractionated radiotherapy. Acta Oncol 2018; 57: 883-94. doi: 10.1080/0284186x.2018.1433874DattaNRStutzERogersSBodisSClinical estimation of α/β values for prostate cancer from isoeffective phase III randomized trials with moderately hypofractionated radiotherapy2018578839410.1080/0284186x.2018.143387429405785Open DOISearch in Google Scholar
Liu HX, Du L, Yu W, Cai BN, Xu SP, Xie CB, et al. Hypofractionated helical tomotherapy for older aged patients with prostate cancer: preliminary results of a Phase I-II trial. Technol Cancer Res Treat 2016; 15: 546-54. doi: 10.1177/1533034615593189LiuHXDuLYuWCaiBNXuSPXieCBet al.Hypofractionated helical tomotherapy for older aged patients with prostate cancer: preliminary results of a Phase I-II trial2016155465410.1177/153303461559318926152749Open DOISearch in Google Scholar
Al-Mamgani A, van Putten WL, Heemsbergen WD, van Leenders GJ, Slot A, Dielwart MF, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72: 980-8. doi: 10.1016/j.ijrobp.2008.02.073Al-MamganiAvan PuttenWLHeemsbergenWDvan LeendersGJSlotADielwartMFet al.Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer200872980810.1016/j.ijrobp.2008.02.07318495377Open DOISearch in Google Scholar
Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016; 17: 1047-60. doi: 10.1016/s1470-2045(16)30102-4DearnaleyDSyndikusIMossopHKhooVBirtleABloomfieldDet al.Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial20161710476010.1016/s1470-2045(16)30102-4Open DOISearch in Google Scholar
Roach M, 3rd, Marquez C, Yuo HS, Narayan P, Coleman L, Nseyo UO, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994; 28: 33-7. doi: 10.1016/0360-3016(94)90138-4RoachMMarquezCYuoHSNarayanPColemanLNseyoUOet al.Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer19942833710.1016/0360-3016(94)90138-47505775Open DOISearch in Google Scholar
Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 2017; 35: 1884-90. doi: 10.1200/ jco.2016.71.7397CattonCNLukkaHGuCSMartinJMSupiotSChungPWMet al.Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer20173518849010.1200/jco.2016.71.7397Open DOISearch in Google Scholar
Roach M, 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003; 21: 1904-11. doi: 10.1200/jco.2003.05.004RoachMDeSilvioMLawtonCUhlVMachtayMSeiderMJet al.Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 941320032119041110.1200/jco.2003.05.00412743142Open DOISearch in Google Scholar
Dess RT, Suresh K, Zelefsky MJ, Freedland SJ, Mahal BA, Cooperberg MR, et al. Development and validation of a clinical prognostic stage group system for nonmetastatic prostate cancer using disease-specific mortality results from the International Staging Collaboration for Cancer of the Prostate. JAMA Oncol 2020; 6: 1912-20. doi: 10.1001/jamaoncol.2020.4922DessRTSureshKZelefskyMJFreedlandSJMahalBACooperbergMRet al.Development and validation of a clinical prognostic stage group system for nonmetastatic prostate cancer using disease-specific mortality results from the International Staging Collaboration for Cancer of the Prostate2020619122010.1001/jamaoncol.2020.4922758223233090219Open DOISearch in Google Scholar
Fine SW. Evolution in prostate cancer staging: Pathology updates from AJCC 8th edition and opportunities that remain. Adv Anat Pathol 2018; 25: 32732. doi: 10.1097/pap.0000000000000200FineSWEvolution in prostate cancer staging: Pathology updates from AJCC 8th edition and opportunities that remain20181519910.1097/pap.000000000000020029870405Open DOISearch in Google Scholar
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-6. doi: 10.1016/0360-3016(95)00060-cCoxJDStetzJPajakTFToxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)1995311341610.1016/0360-3016(95)00060-c7713792Open DOISearch in Google Scholar
Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-6. doi: 10.1016/0197-2456(96)00075-xSchemperMSmithTLA note on quantifying follow-up in studies of failure time199617343610.1016/0197-2456(96)00075-x8889347Open DOISearch in Google Scholar
Edelman S, Liauw SL, Rossi PJ, Cooper S, Jani AB. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes. Int J Radiat Oncol Biol Phys 2012; 83: 1473-9. doi: 10.1016/j.ijrobp.2011.10.036EdelmanSLiauwSLRossiPJCooperSJaniABHigh-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes2012831473910.1016/j.ijrobp.2011.10.03622245201Open DOISearch in Google Scholar
López-Torrecilla J, Pastor-Peidro J, Vicedo-González A, González-Sanchis D, Hernandez-Machancoses A, Almendros-Blanco P, et al. Patterns of treatment failure in patients with prostate cancer treated with 76-80 Gy radiotherapy to the prostate and seminal vesicles ± hormonotherapy. Clin Transl Oncol 2021; 23: 481-90. doi: 10.1007/s12094-020-02437-0López-TorrecillaJPastor-PeidroJVicedo-GonzálezAGonzález-SanchisDHernandez-MachancosesAAlmendros-BlancoPet al.Patterns of treatment failure in patients with prostate cancer treated with 76-80 Gy radiotherapy to the prostate and seminal vesicles ± hormonotherapy2021234819010.1007/s12094-020-02437-032621208Open DOISearch in Google Scholar
Pahlajani N, Ruth KJ, Buyyounouski MK, Chen DY, Horwitz EM, Hanks GE, et al. Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82: 1949-56. doi: 10.1016/j.ijrobp.2011.04.005PahlajaniNRuthKJBuyyounouskiMKChenDYHorwitzEMHanksGEet al.Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer20128219495610.1016/j.ijrobp.2011.04.005382795721763081Open DOISearch in Google Scholar
Scardino P. Update: NCCN prostate cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 2005; 3 Suppl 1: S29-33. PMID: 16280109ScardinoPUpdate: NCCN prostate cancer Clinical Practice Guidelines20053Suppl 1S2933PMID: 16280109Search in Google Scholar
Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8: 475-87. doi: 10.1016/s1470-2045(07)70143-2DearnaleyDPSydesMRGrahamJDAirdEGBottomleyDCowanRAet al.Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial200784758710.1016/s1470-2045(07)70143-217482880Open DOISearch in Google Scholar
Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, et al. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys 2013; 87: 932-8. doi: 10.1016/j.ijrobp.2013.07.041MichalskiJMYanYWatkins-BrunerDBoschWRWinterKGalvinJMet al.Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial201387932810.1016/j.ijrobp.2013.07.041384004424113055Open DOISearch in Google Scholar
Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG Oncology RTOG 0126 randomized clinical trial. JAMA Oncol 2018; 4: e180039. doi: 10.1001/jamaoncol.2018.0039MichalskiJMMoughan JPurdyJBoschWBrunerDWBaharyJPet al.Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG Oncology RTOG 0126 randomized clinical trial20184e18003910.1001/jamaoncol.2018.0039588516029543933Open DOISearch in Google Scholar
Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 2016; 34: 2325-32. doi: 10.1200/jco.2016.67.0448LeeWRDignamJJAminMBBrunerDWLowDSwansonGPet al.Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer20163423253210.1200/jco.2016.67.0448Open DOISearch in Google Scholar
Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008; 71: 330-7. doi: 10.1016/j. ijrobp.2007.10.004CahlonOZelefskyMJShippyAChanHFuksZYamadaYet al.Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes200871330710.1016/j.ijrobp.2007.10.00418164858Open DOISearch in Google Scholar
Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009; 74: 1405-18. doi: 10.1016/j. ijrobp.2008.10.091VianiGAStefanoEJAfonsoSLHigher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials20097414051810.1016/j.ijrobp.2008.10.09119616743Open DOISearch in Google Scholar
Viani GA, Viana BS, Martin JE, Rossi BT, Zuliani G, Stefano EJ. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial. Cancer 2016; 122: 2004-11. doi: 10.1002/ cncr.29983VianiGAVianaBSMartinJERossiBTZulianiGStefanoEJIntensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial201612220041110.1002/cncr.2998327028170Open DOISearch in Google Scholar
Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, et al. Hypofractionated radiation therapy for localized prostate cancer: Executive summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Pract Radiat Oncol 2018; 8: 354-60. doi: 10.1016/j.prro.2018.08.002MorganSCHoffmanKLoblawDABuyyounouskiMKPattonCBarocasDet al.Hypofractionated radiation therapy for localized prostate cancer: Executive summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline201883546010.1016/j.prro.2018.08.00230322661Open DOISearch in Google Scholar
Arcangeli G, Fowler J, Gomellini S, Arcangeli S, Saracino B, Petrongari MG, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011; 79: 1013-21. doi: 10.1016/j. ijrobp.2009.12.045ArcangeliGFowlerJGomelliniSArcangeliSSaracinoBPetrongariMGet al.Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer20117910132110.1016/jijrobp.2009.12.045Open DOISearch in Google Scholar
Arcangeli G, Saracino B, Arcangeli S, Gomellini S, Petrongari MG, Sanguineti G, et al. Moderate hypofractionation in high-risk, organ-confined prostate cancer: Final results of a phase III randomized trial. J Clin Oncol 2017; 35: 1891-7. doi: 10.1200/jco.2016.70.4189ArcangeliGSaracinoBArcangeliSGomelliniSPetrongariMGSanguinetiGet al.Moderate hypofractionation in high-risk, organ-confined prostate cancer: Final results of a phase III randomized trial2017351891710.1200/jco.2016.70.418928355113Open DOISearch in Google Scholar
Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007; 68: 1424-30. doi: 10.1016/j.ijrobp.2007.01.067KupelianPAWilloughbyTRReddyCAKleinEAMahadevanAHypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience20076814243010.1016/j.ijrobp.2007.01.06717544601Open DOISearch in Google Scholar
Kupelian PA, Reddy CA, Klein EA, Willoughby TR. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 2001; 51: 988-93. doi: 10.1016/s0360-3016(01)01730-8KupelianPAReddyCAKleinEAWilloughbyTRShort-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life2001519889310.1016/s0360-3016(01)01730-811704322Open DOISearch in Google Scholar
Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 2005; 63: 1463-8. doi: 10.1016/j.ijrobp.2005.05.054KupelianPAThakkarVVKhuntiaDReddyCAKleinEAMahadevanAHypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes2005631463810.1016/j.ijrobp.2005.05.05416169683Open DOISearch in Google Scholar
Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 2013; 31: 3860-8. doi: 10.1200/jco.2013.51.1972PollackAWalkerGHorwitzEMPriceRFeigenbergSKonskiAAet al.Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer2013313860810.1200/jco.2013.51.1972380592724101042Open DOISearch in Google Scholar
de Vries KC, Wortel RC, Oomen-de Hoop E, Heemsbergen WD, Pos FJ, Incrocci L. Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-Year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial. Int J Radiat Oncol Biol Phys 2020; 106: 108-15. doi: 10.1016/j. ijrobp.2019.09.007de VriesKCWortelRCOomen-de HoopEHeemsbergenWDPosFJIncrocciL.Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-Year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial20201061081510.1016/j.ijrobp.2019.09.00731593756Open DOISearch in Google Scholar
Yin Z, You J, Wang Y, Zhao J, Jiang S, Zhang X, et al. Moderate hypofractionated radiotherapy vs conventional fractionated radiotherapy in localized prostate cancer: a systemic review and meta-analysis from Phase III randomized trials. Onco Targets Ther 2019; 12: 1259-68. doi: 10.2147/ott. S181067YinZYouJWangYZhaoJJiangSZhangXet al.Moderate hypofractionated radiotherapy vs conventional fractionated radiotherapy in localized prostate cancer: a systemic review and meta-analysis from Phase III randomized trials20191212596810.2147/ott.S181067638898030863093Open DOISearch in Google Scholar
Wen N, Kumarasiri A, Nurushev T, Burmeister J, Xing L, Liu D, et al. An assessment of PTV margin based on actual accumulated dose for prostate cancer radiotherapy. Phys Med Biol 2013; 58: 7733-44. doi: 10.1088/00319155/58/21/7733WenNKumarasiriANurushevTBurmeisterJXingLLiuDet al.An assessment of PTV margin based on actual accumulated dose for prostate cancer radiotherapy20135877334410.1088/00319155/58/21/7733Open DOISearch in Google Scholar
Maund IF, Benson RJ, Fairfoul J, Cook J, Huddart R, Poynter A. Image-guided radiotherapy of the prostate using daily CBCT: the feasibility and likely benefit of implementing a margin reduction. Br J Radiol 2014; 87: 20140459. doi: 10.1259/bjr.20140459MaundIFBensonRJFairfoulJCookJHuddartRPoynterAImage-guided radiotherapy of the prostate using daily CBCT: the feasibility and likely benefit of implementing a margin reduction20141519910.1259/bjr.20140459424319725354015Open DOISearch in Google Scholar
Utsunomiya S, Yamamoto J, Tanabe S, Oishi M, Satsuma A, Kaidu M, et al. Complementary relation between the improvement of dose delivery technique and PTV margin reduction in dose-escalated radiation therapy for prostate cancer. Pract Radiat Oncol 2019; 9: 172-8. doi: 10.1016/j. prro.2019.02.001UtsunomiyaSYamamotoJTanabeSOishiMSatsumaAKaiduMet al.Complementary relation between the improvement of dose delivery technique and PTV margin reduction in dose-escalated radiation therapy for prostate cancer20199172810.1016/j.prro.2019.02.00130772440Open DOISearch in Google Scholar
Murray J, Griffin C, Gulliford S, Syndikus I, Staffurth J, Panades M, et al. A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer. Radiother Oncol 2020; 142: 62-71. doi: 10.1016/j.radonc.2019.10.017MurrayJGriffinCGullifordSSyndikusIStaffurthJPanadesMet al.A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer2020142627110.1016/j.radonc.2019.10.017700567331767473Open DOISearch in Google Scholar
Meeks SL, Harmon JF, Jr., Langen KM, Willoughby TR, Wagner TH, Kupelian PA. Performance characterization of megavoltage computed tomography imaging on a helical tomotherapy unit. Med Phys 2005; 32: 2673-81. doi: 10.1118/1.1990289MeeksSLHarmonJF, Jr.LangenKMWilloughbyTRWagnerTHKupelianPAPerformance characterization of megavoltage computed tomography imaging on a helical tomotherapy unit20053226738110.1118/1.199028916193798Open DOISearch in Google Scholar
Murthy V, Krishnatry R, Mallik S, Master Z, Mahantshetty U, Shrivastava S. Helical tomotherapy-based hypofractionated radiotherapy for prostate cancer: a report on the procedure, dosimetry and preliminary clinical outcome. J Cancer Res Ther 2013; 9: 253-60. doi: 10.4103/0973-1482.113378MurthyVKrishnatryRMallikSMasterZMahantshettyUShrivastavaSHelical tomotherapy-based hypofractionated radiotherapy for prostate cancer: a report on the procedure, dosimetry and preliminary clinical outcome201392536010.4103/0973-1482.11337823771369Open DOISearch in Google Scholar
Schiller K, Geier M, Duma MN, Nieder C, Molls M, Combs SE, et al. Definitive, intensity modulated tomotherapy with a simultaneous integrated boost for prostate cancer patients - Long term data on toxicity and biochemical control. Rep Pract Oncol Radiother 2019; 24: 315-21. doi: 10.1016/j.rpor.2019.05.004SchillerKGeierMDumaMNNiederCMollsMCombsSEet al.Definitive, intensity modulated tomotherapy with a simultaneous integrated boost for prostate cancer patients - Long term data on toxicity and biochemical control2019243152110.1016/j.rpor.2019.05.004654318531193851Open DOISearch in Google Scholar
Pommier P, Chabaud S, Lagrange JL, Richaud P, Le Prise E, Wagner JP, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol Biol Phys 2016; 96: 759-69. doi: 10.1016/j. ijrobp.2016.06.2455PommierPChabaudSLagrangeJLRichaudPLe PriseEWagnerJPet al.Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study2016967596910.1016/j.ijrobp.2016.06.245527788949Open DOISearch in Google Scholar
Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, et al. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol 2018; 19: 1504-15. doi: 10.1016/ s1470-2045(18)30528-xRoachMMoughanJLawtonCAFDickerAPZeitzerKLGoreEMet al.Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial20181915041510.1016/s1470-2045(18)30528-x654079730316827Open DOISearch in Google Scholar
Shiota M, Yokomizo A, Takeuchi A, Imada K, Kiyoshima K, Inokuchi J, et al. The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy. J Cancer Res Clin Oncol 2015; 141: 495-503. doi: 10.1007/s00432-014-1828-7ShiotaMYokomizoATakeuchiAImadaKKiyoshimaKInokuchiJet al.The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy201514149550310.1007/s00432-014-1828-725227457Open DOISearch in Google Scholar
Kimura K, Tsuzuki T, Kato M, Saito AM, Sassa N, Ishida R, et al. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate 2014; 74: 680-7. doi: 10.1002/pros.22786KimuraKTsuzukiTKatoMSaitoAMSassaNIshidaRet al.Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens201474680710.1002/pros.2278624481730Open DOISearch in Google Scholar
Kato M, Kimura K, Hirakawa A, Kobayashi Y, Ishida R, Kamihira O, et al. Prognostic parameter for high risk prostate cancer patients at initial presentation. Prostate 2018; 78: 11-6. doi: 10.1002/pros.23438KatoMKimuraKHirakawaAKobayashiYIshidaRKamihiraOet al.Prognostic parameter for high risk prostate cancer patients at initial presentation20187811610.1002/pros.2343829094384Open DOISearch in Google Scholar
Feng FY, Huang HC, Spratt DE, Zhao SG, Sandler HM, Simko JP, et al. Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: An ancillary study of the NRG/RTOG 9601 randomized clinical trial. JAMA Oncol 2021; 7: 544-52. doi: 10.1001/jamaoncol.2020.7671FengFYHuangHCSprattDEZhaoSGSandlerHMSimkoJPet al.Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: An ancillary study of the NRG/RTOG 9601 randomized clinical trial202175445210.1001/jamaoncol.2020.7671787938533570548Open DOISearch in Google Scholar
Syrigos KN, Karapanagiotou E, Harrington KJ. Prostate cancer in the elderly. Anticancer Res 2005; 25: 4527-33SyrigosKNKarapanagiotouEHarringtonKJProstate cancer in the elderly200515452733Search in Google Scholar
Wu YH, Yang WC, Hu YW, Hsieh CM, Yang KL, Lai IC, et al. Definitive radiotherapy for older patients with prostate cancer: Experience of a medical center in Taiwan. Sci Rep 2017; 7: 13880. doi:10.1038/s41598-017-13119-3WuYHYangWCHuYWHsiehCMYangKLLaiICet al.Definitive radiotherapy for older patients with prostate cancer: Experience of a medical center in Taiwan20171519910.1038/s41598-017-13119-3565567029066834Open DOISearch in Google Scholar
Dell’Oglio P, Boehm K, Trudeau V, Tian Z, Larcher A, Leyh-Bannurah SR, et al. Survival after conservative management versus external beam radiation therapy in elderly patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2016; 96: 1037-45. doi: 10.1016/j.ijrobp.2016.05.004Dell’OglioPBoehmKTrudeauVTianZLarcherALeyh-BannurahSRet al.Survival after conservative management versus external beam radiation therapy in elderly patients with localized prostate cancer20169610374510.1016/j.ijrobp.2016.05.00427478167Open DOISearch in Google Scholar
Wilson JM, Dearnaley DP, Syndikus I, Khoo V, Birtle A, Bloomfield D, et al. The Efficacy and safety of conventional and hypofractionated high-dose radiation therapy for prostate cancer in an elderly population: A subgroup analysis of the CHHiP trial. Int J Radiat Oncol Biol Phys 2018; 100: 1179-89. doi: 10.1016/j.ijrobp.2018.01.016WilsonJMDearnaleyDPSyndikusIKhooVBirtleABloomfieldDet al.The Efficacy and safety of conventional and hypofractionated high-dose radiation therapy for prostate cancer in an elderly population: A subgroup analysis of the CHHiP trial201810011798910.1016/j.ijrobp.2018.01.016631445229722660Open DOISearch in Google Scholar
Cuccia F, Fiorentino A, Corrao S, Mortellaro G, Valenti V, Tripoli A, et al. Moderate hypofractionated helical tomotherapy for prostate cancer in a cohort of older patients: a mono-institutional report of toxicity and clinical outcomes. Aging Clin Exp Res 2020; 32: 747-53. doi: 10.1007/s40520-019-01243-1CucciaFFiorentinoACorraoSMortellaroGValentiVTripoliAet al.Moderate hypofractionated helical tomotherapy for prostate cancer in a cohort of older patients: a mono-institutional report of toxicity and clinical outcomes2020327475310.1007/s40520-019-01243-131267377Open DOISearch in Google Scholar
Sujenthiran A, Parry M, Nossiter J, Berry B, Cathcart PJ, Clarke NW, et al. Comparison of treatment-related toxicity with hypofractionated or conventionally fractionated radiation therapy for prostate cancer: A National Population-Based Study. Clin Oncol 2020; 32: 501-8. doi: 10.1016/j. clon.2020.02.004SujenthiranAParryMNossiterJBerryBCathcartPJClarkeNWet al.Comparison of treatment-related toxicity with hypofractionated or conventionally fractionated radiation therapy for prostate cancer: A National Population-Based Study202032501810.1016/j.clon.2020.02.00432143901Open DOISearch in Google Scholar